Cardiac Drug Safety :: a Bench to Bedside Approach.
Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Singapore :
World Scientific,
2012.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr. |
| Beschreibung: | Variability of repolarization. |
| Beschreibung: | 1 online resource (189 pages) |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9789814317467 9814317462 1280669225 9781280669224 9786613646156 6613646156 |
Internformat
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn794328376 | ||
| 003 | OCoLC | ||
| 005 | 20240705115654.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 120528s2012 si ob 001 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d OCLCQ |d LGG |d YDXCP |d N$T |d IDEBK |d OCLCQ |d CDX |d DEBSZ |d OCLCQ |d E7B |d STF |d OCLCF |d DEBBG |d UKDOC |d OCLCQ |d OCL |d OCLCQ |d D6H |d LOA |d OCLCO |d JBG |d OCLCO |d OCLCA |d AGLDB |d OCLCO |d MOR |d PIFAG |d ZCU |d OCLCO |d OCLCQ |d MERUC |d OCLCO |d OCLCQ |d OCLCO |d OCLCA |d U3W |d OCLCO |d WRM |d VNS |d OCLCO |d VTS |d OCLCO |d NRAMU |d ICG |d OCLCO |d TOF |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d OCLCO |d OTZ |d OCLCO |d OCLCA |d REC |d DKC |d OCLCO |d OCLCQ |d OCLCO |d M8D |d OCLCO |d UKAHL |d OCLCQ |d OCLCO |d OCLCA |d UKCRE |d AJS |d LUU |d OCLCO |d OCLCQ |d QGK |d OCLCO |d OCLCL |d SXB |d OCLCQ | ||
| 019 | |a 793804672 |a 794902679 |a 797852507 |a 817084766 |a 961685992 |a 966211954 |a 988409859 |a 988476737 |a 992030749 |a 1037737880 |a 1038664895 |a 1045555365 |a 1065914499 |a 1086551858 |a 1153534694 |a 1259218625 | ||
| 020 | |a 9789814317467 |q (electronic bk.) | ||
| 020 | |a 9814317462 |q (electronic bk.) | ||
| 020 | |a 1280669225 | ||
| 020 | |a 9781280669224 | ||
| 020 | |z 9789814317450 | ||
| 020 | |z 9814317454 | ||
| 020 | |a 9786613646156 | ||
| 020 | |a 6613646156 | ||
| 035 | |a (OCoLC)794328376 |z (OCoLC)793804672 |z (OCoLC)794902679 |z (OCoLC)797852507 |z (OCoLC)817084766 |z (OCoLC)961685992 |z (OCoLC)966211954 |z (OCoLC)988409859 |z (OCoLC)988476737 |z (OCoLC)992030749 |z (OCoLC)1037737880 |z (OCoLC)1038664895 |z (OCoLC)1045555365 |z (OCoLC)1065914499 |z (OCoLC)1086551858 |z (OCoLC)1153534694 |z (OCoLC)1259218625 | ||
| 043 | |a n-cn--- | ||
| 050 | 4 | |a QC903 .S86 2012 | |
| 060 | 0 | 0 | |a 2012 D-923 |
| 060 | 1 | 0 | |a QV 152 |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a TEC |x 010010 |2 bisacsh | |
| 072 | 7 | |a MMG |2 bicssc | |
| 082 | 7 | |a 363.738/74 |a 363.73874 |a 615.71 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Killeen, Matthew J. | |
| 245 | 1 | 0 | |a Cardiac Drug Safety : |b a Bench to Bedside Approach. |
| 260 | |a Singapore : |b World Scientific, |c 2012. | ||
| 300 | |a 1 online resource (189 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 505 | 0 | |a Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels. | |
| 505 | 8 | |a Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References. | |
| 505 | 8 | |a Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts. | |
| 505 | 8 | |a Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction. | |
| 505 | 8 | |a Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia. | |
| 500 | |a Variability of repolarization. | ||
| 520 | |a Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr. | ||
| 588 | 0 | |a Print version record. | |
| 504 | |a Includes bibliographical references and index. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Arrhythmia |x Treatment. |0 http://id.loc.gov/authorities/subjects/sh86003036 | |
| 650 | 0 | |a Drugs |x Safety regulations |z Canada. | |
| 650 | 2 | |a Drug-Related Side Effects and Adverse Reactions |x prevention & control | |
| 650 | 2 | |a Heart |x drug effects | |
| 650 | 6 | |a Arythmie |x Traitement. | |
| 650 | 6 | |a Médicaments |x Sécurité |x Règlements |z Canada. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a TECHNOLOGY & ENGINEERING |x Environmental |x Pollution Control. |2 bisacsh | |
| 650 | 7 | |a Arrhythmia |x Treatment |2 fast | |
| 650 | 7 | |a Drugs |x Safety regulations |2 fast | |
| 651 | 7 | |a Canada |2 fast |1 https://id.oclc.org/worldcat/entity/E39PBJkMHVW4rfVXPrhVP4VwG3 | |
| 758 | |i has work: |a Cardiac drug safety (Text) |1 https://id.oclc.org/worldcat/entity/E39PCFvK6HCrcGxT9fJyW9jmYd |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Killeen, Matthew J. |t Cardiac Drug Safety : A Bench to Bedside Approach. |d Singapore : World Scientific, ©2012 |z 9789814317450 |
| 856 | 1 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178 |3 Volltext | |
| 856 | 1 | |l CBO01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178 |3 Volltext | |
| 938 | |a 123Library |b 123L |n 114800 | ||
| 938 | |a Askews and Holts Library Services |b ASKH |n AH25565234 | ||
| 938 | |a Coutts Information Services |b COUT |n 23981151 | ||
| 938 | |a EBL - Ebook Library |b EBLB |n EBL919080 | ||
| 938 | |a ebrary |b EBRY |n ebr10563572 | ||
| 938 | |a EBSCOhost |b EBSC |n 457178 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 364615 | ||
| 938 | |a YBP Library Services |b YANK |n 7280427 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn794328376 |
|---|---|
| _version_ | 1813903436865863681 |
| adam_text | |
| any_adam_object | |
| author | Killeen, Matthew J. |
| author_facet | Killeen, Matthew J. |
| author_role | |
| author_sort | Killeen, Matthew J. |
| author_variant | m j k mj mjk |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | Q - Science |
| callnumber-label | QC903 |
| callnumber-raw | QC903 .S86 2012 |
| callnumber-search | QC903 .S86 2012 |
| callnumber-sort | QC 3903 S86 42012 |
| callnumber-subject | QC - Physics |
| collection | ZDB-4-EBA |
| contents | Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels. Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References. Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts. Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction. Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia. |
| ctrlnum | (OCoLC)794328376 |
| dewey-full | 363.738/74 363.73874 615.71 |
| dewey-hundreds | 300 - Social sciences 600 - Technology (Applied sciences) |
| dewey-ones | 363 - Other social problems and services 615 - Pharmacology and therapeutics |
| dewey-raw | 363.738/74 363.73874 615.71 |
| dewey-search | 363.738/74 363.73874 615.71 |
| dewey-sort | 3363.738 274 |
| dewey-tens | 360 - Social problems and services; associations 610 - Medicine and health |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07424cam a2200817Mi 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn794328376</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20240705115654.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |n|---|||||</controlfield><controlfield tag="008">120528s2012 si ob 001 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">EBLCP</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">EBLCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">LGG</subfield><subfield code="d">YDXCP</subfield><subfield code="d">N$T</subfield><subfield code="d">IDEBK</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">CDX</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">E7B</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCF</subfield><subfield code="d">DEBBG</subfield><subfield code="d">UKDOC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">D6H</subfield><subfield code="d">LOA</subfield><subfield code="d">OCLCO</subfield><subfield code="d">JBG</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCO</subfield><subfield code="d">MOR</subfield><subfield code="d">PIFAG</subfield><subfield code="d">ZCU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">U3W</subfield><subfield code="d">OCLCO</subfield><subfield code="d">WRM</subfield><subfield code="d">VNS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VTS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">NRAMU</subfield><subfield code="d">ICG</subfield><subfield code="d">OCLCO</subfield><subfield code="d">TOF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AU@</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OTZ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">REC</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">UKAHL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">UKCRE</subfield><subfield code="d">AJS</subfield><subfield code="d">LUU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">QGK</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield><subfield code="d">SXB</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">793804672</subfield><subfield code="a">794902679</subfield><subfield code="a">797852507</subfield><subfield code="a">817084766</subfield><subfield code="a">961685992</subfield><subfield code="a">966211954</subfield><subfield code="a">988409859</subfield><subfield code="a">988476737</subfield><subfield code="a">992030749</subfield><subfield code="a">1037737880</subfield><subfield code="a">1038664895</subfield><subfield code="a">1045555365</subfield><subfield code="a">1065914499</subfield><subfield code="a">1086551858</subfield><subfield code="a">1153534694</subfield><subfield code="a">1259218625</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9789814317467</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9814317462</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1280669225</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781280669224</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9789814317450</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9814317454</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9786613646156</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">6613646156</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)794328376</subfield><subfield code="z">(OCoLC)793804672</subfield><subfield code="z">(OCoLC)794902679</subfield><subfield code="z">(OCoLC)797852507</subfield><subfield code="z">(OCoLC)817084766</subfield><subfield code="z">(OCoLC)961685992</subfield><subfield code="z">(OCoLC)966211954</subfield><subfield code="z">(OCoLC)988409859</subfield><subfield code="z">(OCoLC)988476737</subfield><subfield code="z">(OCoLC)992030749</subfield><subfield code="z">(OCoLC)1037737880</subfield><subfield code="z">(OCoLC)1038664895</subfield><subfield code="z">(OCoLC)1045555365</subfield><subfield code="z">(OCoLC)1065914499</subfield><subfield code="z">(OCoLC)1086551858</subfield><subfield code="z">(OCoLC)1153534694</subfield><subfield code="z">(OCoLC)1259218625</subfield></datafield><datafield tag="043" ind1=" " ind2=" "><subfield code="a">n-cn---</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QC903 .S86 2012</subfield></datafield><datafield tag="060" ind1="0" ind2="0"><subfield code="a">2012 D-923</subfield></datafield><datafield tag="060" ind1="1" ind2="0"><subfield code="a">QV 152</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">TEC</subfield><subfield code="x">010010</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MMG</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">363.738/74</subfield><subfield code="a">363.73874</subfield><subfield code="a">615.71</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Killeen, Matthew J.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardiac Drug Safety :</subfield><subfield code="b">a Bench to Bedside Approach.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Singapore :</subfield><subfield code="b">World Scientific,</subfield><subfield code="c">2012.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (189 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Variability of repolarization.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Arrhythmia</subfield><subfield code="x">Treatment.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh86003036</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Safety regulations</subfield><subfield code="z">Canada.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug-Related Side Effects and Adverse Reactions</subfield><subfield code="x">prevention & control</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Heart</subfield><subfield code="x">drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Arythmie</subfield><subfield code="x">Traitement.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Sécurité</subfield><subfield code="x">Règlements</subfield><subfield code="z">Canada.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TECHNOLOGY & ENGINEERING</subfield><subfield code="x">Environmental</subfield><subfield code="x">Pollution Control.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Arrhythmia</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="x">Safety regulations</subfield><subfield code="2">fast</subfield></datafield><datafield tag="651" ind1=" " ind2="7"><subfield code="a">Canada</subfield><subfield code="2">fast</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PBJkMHVW4rfVXPrhVP4VwG3</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Cardiac drug safety (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCFvK6HCrcGxT9fJyW9jmYd</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Killeen, Matthew J.</subfield><subfield code="t">Cardiac Drug Safety : A Bench to Bedside Approach.</subfield><subfield code="d">Singapore : World Scientific, ©2012</subfield><subfield code="z">9789814317450</subfield></datafield><datafield tag="856" ind1="1" ind2=" "><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="1" ind2=" "><subfield code="l">CBO01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">123Library</subfield><subfield code="b">123L</subfield><subfield code="n">114800</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Askews and Holts Library Services</subfield><subfield code="b">ASKH</subfield><subfield code="n">AH25565234</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Coutts Information Services</subfield><subfield code="b">COUT</subfield><subfield code="n">23981151</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL919080</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10563572</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">457178</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">364615</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">7280427</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield></record></collection> |
| geographic | Canada fast https://id.oclc.org/worldcat/entity/E39PBJkMHVW4rfVXPrhVP4VwG3 |
| geographic_facet | Canada |
| id | ZDB-4-EBA-ocn794328376 |
| illustrated | Not Illustrated |
| indexdate | 2024-10-25T16:18:40Z |
| institution | BVB |
| isbn | 9789814317467 9814317462 1280669225 9781280669224 9786613646156 6613646156 |
| language | English |
| oclc_num | 794328376 |
| open_access_boolean | |
| owner | MAIN |
| owner_facet | MAIN |
| physical | 1 online resource (189 pages) |
| psigel | ZDB-4-EBA |
| publishDate | 2012 |
| publishDateSearch | 2012 |
| publishDateSort | 2012 |
| publisher | World Scientific, |
| record_format | marc |
| spelling | Killeen, Matthew J. Cardiac Drug Safety : a Bench to Bedside Approach. Singapore : World Scientific, 2012. 1 online resource (189 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels. Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References. Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts. Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction. Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia. Variability of repolarization. Ensuring the safety of new medical products remains a major challenge for the pharmaceutical industry. Cardiac safety, particularly drug-induced heart rhythm abnormalities, remains an important cause of pipeline attrition and has resulted in countless major product recalls or label changes. The risk of encountering this major adverse event continues to shape the drug development and regulatory landscape. Extensive research over the past decade has shed light on the root causes of arrhythmias that are triggered by medications and has helped drive, and optimize, drug safety testing. However, curr. Print version record. Includes bibliographical references and index. English. Arrhythmia Treatment. http://id.loc.gov/authorities/subjects/sh86003036 Drugs Safety regulations Canada. Drug-Related Side Effects and Adverse Reactions prevention & control Heart drug effects Arythmie Traitement. Médicaments Sécurité Règlements Canada. MEDICAL Pharmacology. bisacsh TECHNOLOGY & ENGINEERING Environmental Pollution Control. bisacsh Arrhythmia Treatment fast Drugs Safety regulations fast Canada fast https://id.oclc.org/worldcat/entity/E39PBJkMHVW4rfVXPrhVP4VwG3 has work: Cardiac drug safety (Text) https://id.oclc.org/worldcat/entity/E39PCFvK6HCrcGxT9fJyW9jmYd https://id.oclc.org/worldcat/ontology/hasWork Print version: Killeen, Matthew J. Cardiac Drug Safety : A Bench to Bedside Approach. Singapore : World Scientific, ©2012 9789814317450 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178 Volltext CBO01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178 Volltext |
| spellingShingle | Killeen, Matthew J. Cardiac Drug Safety : a Bench to Bedside Approach. Foreword; "Et causae quoque aestimatio saepe morbum solvit"* [Celsus: Prooemium 69, De Medicina]; Preface; Chapter 1 Challenges Facing the Pharmaceutical Industry in the 21st Century; Introduction; The Impact of Cardiac Toxicity on the Pharmaceutical Industry; References; Chapter 2 The Cellular Basis of Cardiac Electrophysiology; Introduction; The Initiation of the Heart Beat; The Ventricular Cardiac Action Potential; The Relationship Between the Cardiac Action Potential and the Electrocardiogram; Ion Channels Underlying the Cardiac Action Potential; Sodium channels. Calcium channelsPotassium channels; Cardiac potassium channels; The transient outward potassium channel; Delayed rectifier potassium channels; The ultra rapid delayed rectifier potassium channel; The HERG potassium channel; The slowly activating delayed rectifier potassium channel; Inwardly rectifying potassium channels; Species-dependent variability of potassium channels; Potassium channel subunits; Summary; References; Chapter 3 Clinical Arrhythmia Syndromes; Introduction; The Long QT Syndrome; Congenital Long QT Syndrome; Drug-Induced QT Prolongation; Summary; References. Chapter 4 The Mechanisms Underlying Cardiac ArrhythmiasIntroduction; Mechanisms Underlying Cardiac Arrhythmias; Abnormal Automaticity; Early and Delayed Afterdepolarizations; Re-entry; Transmural Dispersion of Repolarization; How does Action Potential and QT Prolongation Generate Arrhythmias?; Does the M-Cell Play a Role in Arrhythmia Induction in Humans?; Using Mouse Models to Study Arrhythmia Mechanisms; Experimental Studies Exploring the Relationship Between Changes in Transmural Repolarization Gradients and Arrhythmias in Mouse Hearts. Arrhythmia Mechanisms and Novel Antiarrhythmic Approaches Identified Using the Hypokalemic Mouse ModelSummary; References; Chapter 5 The Mechanisms Underlying Drug-Induced Arrhythmias; Introduction; The Classical Model of Drug-Induced QT Prolongation and Proarrhythmia: HERG Blockade; Additional Mechanisms Contributing to Drug-Induced Arrhythmias; Drug-Induction Activation of Depolarizing Ion Channels; Drug-Induced Changes in Ion Channel Expression; Drug-Induced Sodium Channel Dysfunction; Summary; References; Chapter 6 Assessing Cardiac Safety in Drug Development; Introduction. Preclinical Evaluation of Cardiac Drug SafetyThe ICH S7B Guidelines; Single Cell Safety Studies; The Purkinje Fiber Model; The Ventricular Wedge Model; Isolated Heart Models; In Vivo Models; The Impact of Species-Related Differences in Cardiac Electrophysiology on Preclinical Drug Safety Assessment; Methods to Provoke Arrhythmias in Preclinical Studies; Programmed electrical stimulation; Reductions in the extracellular K+ concentration; Clinical Evaluation of Cardiac Safety; The Thorough QT study; Thorough QT study design; Additional Biomarkers to Detect Drug-Induced Proarrhythmia. Arrhythmia Treatment. http://id.loc.gov/authorities/subjects/sh86003036 Drugs Safety regulations Canada. Drug-Related Side Effects and Adverse Reactions prevention & control Heart drug effects Arythmie Traitement. Médicaments Sécurité Règlements Canada. MEDICAL Pharmacology. bisacsh TECHNOLOGY & ENGINEERING Environmental Pollution Control. bisacsh Arrhythmia Treatment fast Drugs Safety regulations fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh86003036 |
| title | Cardiac Drug Safety : a Bench to Bedside Approach. |
| title_auth | Cardiac Drug Safety : a Bench to Bedside Approach. |
| title_exact_search | Cardiac Drug Safety : a Bench to Bedside Approach. |
| title_full | Cardiac Drug Safety : a Bench to Bedside Approach. |
| title_fullStr | Cardiac Drug Safety : a Bench to Bedside Approach. |
| title_full_unstemmed | Cardiac Drug Safety : a Bench to Bedside Approach. |
| title_short | Cardiac Drug Safety : |
| title_sort | cardiac drug safety a bench to bedside approach |
| title_sub | a Bench to Bedside Approach. |
| topic | Arrhythmia Treatment. http://id.loc.gov/authorities/subjects/sh86003036 Drugs Safety regulations Canada. Drug-Related Side Effects and Adverse Reactions prevention & control Heart drug effects Arythmie Traitement. Médicaments Sécurité Règlements Canada. MEDICAL Pharmacology. bisacsh TECHNOLOGY & ENGINEERING Environmental Pollution Control. bisacsh Arrhythmia Treatment fast Drugs Safety regulations fast |
| topic_facet | Arrhythmia Treatment. Drugs Safety regulations Canada. Drug-Related Side Effects and Adverse Reactions prevention & control Heart drug effects Arythmie Traitement. Médicaments Sécurité Règlements Canada. MEDICAL Pharmacology. TECHNOLOGY & ENGINEERING Environmental Pollution Control. Arrhythmia Treatment Drugs Safety regulations Canada |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=457178 |
| work_keys_str_mv | AT killeenmatthewj cardiacdrugsafetyabenchtobedsideapproach |